Molecular Characteristics of Brodalumab in Hidradenitis Suppurativa

Overview

Hidradenitis suppurativa is a disease involving skin folds, causing swelling of the skin and surrounding tissues, pain, and foul-smelling discharges. Effective treatment options are lacking. Recently, clinical trials conducted in our lab found Brodalumab was an effective drug for this disease. Weekly dosing achieved superior therapeutic outcomes compared to a dosing given once in every other week. Brodalumab was safe in both regimens, but blood and tissue studies to better understand this response are still needed. By performing this small pilot study and collecting blood and tissue samples from participants treated with Brodalumab once weekly we would like to better characterize the molecular response to this treatment, identify blood and tissue markers reflecting disease severity, and better understand disease mechanisms.

Full Title of Study: “A Small Pilot Study to Develop Biomarkers of Weekly Brodalumab Administration in Hidradenitis Suppurativa Patients”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Basic Science
    • Masking: None (Open Label)
  • Study Primary Completion Date: July 25, 2022

Interventions

  • Drug: Brodalumab
    • Subcutaneously Brodalumab/Siliq, 210mg/1.5ml once a week

Arms, Groups and Cohorts

  • Experimental: Brodalumab treated moderate-to-severe HS patients
    • Weekly Brodalumab treatment 210mg/1.5ml, given subcutaneously for 12 weeks.

Clinical Trial Outcome Measures

Primary Measures

  • Interleukin-17 receptor A (IL-17RA) saturation during brodalumab administration at week 12 vs baseline
    • Time Frame: 12 weeks
    • Percentage change in saturation

Secondary Measures

  • Change in levels of IL-17A, IL-17C, IL-17, CXCL1, and CXCL8
    • Time Frame: 12 weeks
    • In Brodalumab treated participants at week 12 compared with baseline
  • Correlate IL-17R saturation (measured by the frequencies of immune cells positive to IL-17RA by flow cytometry) with clinical measures, such as pain or the Hidradenitis Suppurativa Severity Score System (IHS4)
    • Time Frame: 12 weeks
    • In Brodalumab treated participants at week 12 compared with baseline

Participating in This Clinical Trial

Inclusion Criteria

  • Confirmed clinical diagnosis of Hidradenitis Suppurativa by the Principal Investigator – Age 18 to 99 years old – Moderate to severe Hidradenitis Suppurativa with draining tunnels (Hidradenitis Suppurativa Severity Score System/IHS4>4) – Must have medical insurance that is willing to pay for the study drug throughout the duration of the study Exclusion Criteria:

  • Inflammatory Bowel Disease – HIV Positive – Active Hepatitis B or C Infection – Pregnant or Breastfeeding – No concurrent use of any systemic antibiotics/retinoids/immunosuppressants/biologics (require washout period of >5 half-lives) – A Score of >10 on the Beck's Depression Inventory (BDI) or on the Patient Health Questionnaire (PHQ)-9 – History of Keloid Scarring – Any medical, psychological or social condition that, in the opinion of the Investigator, would jeopardize the health or well-being of the participant during any study procedures or the integrity of the data

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 99 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Rockefeller University
  • Provider of Information About this Clinical Study
    • Principal Investigator: Yael Renert-Yuval, Instructor in clinical investigation – Rockefeller University
  • Overall Official(s)
    • Yael Renert-Yuval, MD, Principal Investigator, The Rockefeller University

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.